Affordable Access to Essential Medication in Developing Countries: Conflicts between Ethical and Economic Imperatives

  title={Affordable Access to Essential Medication in Developing Countries: Conflicts between Ethical and Economic Imperatives},
  author={Udo Schuklenk and Richard Edmund Ashcroft},
  journal={HEN: HIV/AIDS (Sub-Topic)},
Recent economic and political advances in developing countries on the African continent and South East Asia are threatened by the rising death and morbidity rates of HIV/AIDS. In the first part of this paper we explain the reasons for the absence of affordable access to essential AIDS medication. In the second part we take a closer look at some of the pivotal frameworks relevant for this situation and undertake an ethical analysis of these frameworks. In the third part we discuss a few of the… 
Access to Essential Drugs: the Ethical Challenge of Allocating Obligations
There is still a huge gap between the potential to save millions of lives with safe and cost-effective drugs and the sad reality of extremely high morbidity and mortality in most low-income countries of the world.
Global Health Disparity and Pharmaceutical Companies’ Obligation to Assist
This chapter critically explores the extent to which pharmaceutical companies have a moral obligation to assist poor patients in least developed countries (LDCs) who currently have no or inadequate
Improving access to HIV/AIDS treatment in Brazil : when are compulsory licenses effective in price negotiations?
Since 1996, Brazil has an anti-AIDS programme that offers universal and free access to antiretroviral through the public-sector health system. An important part of the successful implementation of
Pharmaceutical Corporations and the Duty to Aid in HIV/AIDS Epidemic
  • A. Ho
  • Political Science, Medicine
  • 2005
This essay will focus on the HIV/AIDS epidemic in LDCs and examine whether or not multinational pharmaceutical corporations that pro duce AIDS medication have a moral duty to help ease the disproportionate disease burden.
Moral Obligation of Pharmaceutical Companies towards HIV Victims in Developing Countries
The objective of the paper is to analyze whether that the pharmaceutical companies producing HIV drugs have moral obligation(s) towards the HIV victims in developing countries who don‟t have access
Global Health and Global Health Ethics: Justice and research in developing countries
Clinical research is a morally complex activity. When properly conducted, it represents a powerful tool for generating information and knowledge that often cannot be obtained by other means. When
Antiretroviral Treatment in Sub-Saharan Africa
There are no conclusive and exhaustive studies of ART adherence and its challenges in the sub-Saharan Africa region which has the largest number of HIV infections in the world and substantial areas for improvement of ART programmes in sub-Sahara African countries.
Cost-effectiveness of managing HIV infection
A dramatic decrease of South Africa’s and other African states’ domestic product in the coming years is predicted, with the world economical consequences from the HIV pandemic.


Social responsibility and global pharmaceutical companies.
  • N. Daniels
  • Political Science
    Developing world bioethics
  • 2001
Skeptical of the solution David Resnik describes which appeals to the respective `social responsibilities of global pharmaceutical companies and developing countries and not persuaded the authors can derive his claims about such responsibilities in the way he does or that appealing to them solves the problems of commitment and enforcement that must be addressed in any realistic solution.
Some questions about the moral responsibilities of drug companies in developing countries.
  • D. Brock
  • Medicine
    Developing world bioethics
  • 2001
David Resnik argues that drug companies have social responsibilities including moral obligations based in beneficence and justice to help meet this need by such practices as drug giveaways discount pricing and special licensing arrangements but this responsibility is contingent on developing countries establishing a business climate in which drug companies can expect to make reasonable profits.
Developing drugs for the developing world: an economic, legal, moral, and political dilemma.
  • D. Resnik
  • Business
    Developing world bioethics
  • 2001
Overall, this paper advocates for reciprocity and cooperation between pharmaceutical companies and developing nations to address the problem of developing drugs for the developing world.
The politics of the private finance initiative and the new NHS
The government has consistently argued that the private finance initiative is no more than a procurement policy, with no implications for services other than increased efficiency, however, this ignores the importance of public-private partnerships to the government's overall agenda.
How Europe Underdeveloped Africa
Preface Addition to the preface Introduction Chapter One - Some Questions on Development What is Development What is Underdevelopment? Chapter Two - How Africa Developed Before the Coming of the
End of Life.
Upon request, the hospital will provide each adult patient with information about their rights under Washington (WA) state law to make decision concerning such medical care, including the right to
Why Don't We Enforce Existing Drug Price Controls? The Unrecognized and Unenforced Reasonable Pricing Requirements Imposed upon Patents Deriving in Whole or in Part from Federally-Funded Research
Rising prescription drug prices have become a pressing national issue. Hidden from most public discussions is the nature of the public/private relationship when government funds part or all of the
Toronto research funding dispute
A dispute over research sponsored by a pharmaceutical company at a leading Canadian hospital has been resolved after consultation with outside research experts and the researcher is reinstated to her previous academic position.